Friday, June 19, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 11 of 1,261
  1. US 12427197

    Methods of producing cobalt nanoparticles and hollow metal nanospheres

    The Regents of the University of California · Granted Sep 30, 2025 · Expires Sep 25, 2045

    granted
  2. US 12428403

    N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as SSTR4 agonists

    Takeda Pharmaceutical Company Limited · Granted Sep 30, 2025 · Expires Sep 25, 2045

    granted
  3. US 12427151

    Compositions and method of treating cancer

    The Regents of the University of California · Granted Sep 30, 2025 · Expires Sep 25, 2045

    granted
  4. US 12427132

    Method of improving sleep

    VANDA PHARMACEUTICALS INC. · Granted Sep 30, 2025 · Expires Sep 25, 2045

    granted
  5. US 12428463

    Chimeric antigen receptors targeting abnormal glycobiology

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Sep 30, 2025 · Expires Sep 25, 2045

    granted
  6. US 12428489

    Human PD-L2 antibodies and methods of use therefor

    The Board of Regents of the University of Texas System · Granted Sep 30, 2025 · Expires Sep 25, 2045

    granted
  7. US 12428487

    Complexes comprising an anti-transferrin receptor antibody linked to an oligonicleotide and method of delivering oligonucleotide to a subject

    Dyne Therapeutics, Inc. · Granted Sep 30, 2025 · Expires Sep 25, 2045

    granted
  8. US 12428470

    Compositions containing activatable antibodies

    CytomX Therapeutics, Inc. · Granted Sep 30, 2025 · Expires Sep 25, 2045

    granted
  9. WO 2025198916

    ANTICORPS ANTI-TAU

    ABBVIE INC [US] · Granted Sep 25, 2025 · Expires Sep 20, 2045

    granted
  10. US 2025295738

    Long-Acting Growth Hormone Dosage Forms With Superior Efficacy to Daily Somatropin

    ASCENDIS PHARMA ENDOCRINOLOGY DIV A/S [DK] · Granted Sep 25, 2025 · Expires Sep 20, 2045

    granted
  11. US 12421282

    Compositions and methods for the treatment of metabolic and liver disorders

    Viking Therapeutics, Inc. · Granted Sep 23, 2025 · Expires Sep 18, 2045

    granted
  12. US 12421308

    Anti-G-CSF antibodies and uses thereof

    ME Therapeutics Inc. · Granted Sep 23, 2025 · Expires Sep 18, 2045

    granted
  13. US 12421280

    Insulin like growth factor binding protein bioactive peptide fragments

    Northwestern University · Granted Sep 23, 2025 · Expires Sep 18, 2045

    granted
  14. US 12419958

    Clinical formulations

    Astellas Institute for Regenerative Medicine · Granted Sep 23, 2025 · Expires Sep 18, 2045

    granted
  15. US 12421273

    Ectonucleotidase inhibitors and methods of use thereof

    ANTENGENE THERAPEUTICS LIMITED · Granted Sep 23, 2025 · Expires Sep 18, 2045

    granted
  16. US 12421315

    CLL-1 targeted immunotherapies

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 23, 2025 · Expires Sep 18, 2045

    granted
  17. US 12420085

    Synergistic therapies for inter vertebral disc degeneration

    Discure Technologies Ltd · Granted Sep 23, 2025 · Expires Sep 18, 2045

    granted
  18. US 12419895

    Methods for treating subjects with Prader-Willi syndrome

    ESSENTIALIS, INC. · Granted Sep 23, 2025 · Expires Sep 18, 2045

    granted
  19. US 12421269

    SGLT2/DPP4 inhibitor and application thereof

    CGeneTech (Suzhou, China) CO., Ltd. · Granted Sep 23, 2025 · Expires Sep 18, 2045

    granted
  20. US 12421316

    Bispecific immunotoxins targeting human CD25+CCR4+ tumors and regulatory T-cells

    The Regents of the University of Colorado, a Body Corporate · Granted Sep 23, 2025 · Expires Sep 18, 2045

    granted
  21. US 12419942

    Use of the Salmonella spp type III secretion proteins as a protective vaccination

    The Board of Regents for Oklahoma State University · Granted Sep 23, 2025 · Expires Sep 18, 2045

    granted
  22. US 12421220

    Bicyclic-substituted glutarimide cereblon binders

    C4 THERAPEUTICS, INC. · Granted Sep 23, 2025 · Expires Sep 18, 2045

    granted
  23. US 12419866

    Compounds and methods for treating an epileptic disorder

    The Regents of the University of California · Granted Sep 23, 2025 · Expires Sep 18, 2045

    granted
  24. US 12419888

    Methods of treating elevated plasma cholesterol

    INSTITUT DE CARDIOLOGIE DE MONTREAL · Granted Sep 23, 2025 · Expires Sep 18, 2045

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.